Limits...
Gigantol Suppresses Cancer Stem Cell-Like Phenotypes in Lung Cancer Cells.

Bhummaphan N, Chanvorachote P - Evid Based Complement Alternat Med (2015)

Bottom Line: Importantly, gigantol significantly reduced the ability of the cancer cells to form tumor spheroids, a critical hallmark of CSCs.Concomitantly, the treatment of the compound was shown to reduce well-known lung CSCs markers, including CD133 and ALDH1A1.In conclusion, gigantol possesses CSCs suppressing activity which may facilitate the development of this compound for therapeutic approaches by targeting CSCs.

View Article: PubMed Central - PubMed

Affiliation: Cell-Based Drug and Health Product Development Research Unit, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok 10330, Thailand.

ABSTRACT
As cancer stem cells (CSCs) contribute to malignancy, metastasis, and relapse of cancers, potential of compound in inhibition of CSCs has garnered most attention in the cancer research as well as drug development fields recently. Herein, we have demonstrated for the first time that gigantol, a pure compound isolated from Dendrobium draconis, dramatically suppressed stem-like phenotypes of human lung cancer cells. Gigantol at nontoxic concentrations significantly reduced anchorage-independent growth and survival of the cancer cells. Importantly, gigantol significantly reduced the ability of the cancer cells to form tumor spheroids, a critical hallmark of CSCs. Concomitantly, the treatment of the compound was shown to reduce well-known lung CSCs markers, including CD133 and ALDH1A1. Moreover, we revealed that gigantol decreased stemness in the cancer cells by suppressing the activation of protein kinase B (Akt) signal which in turn decreased the cellular levels of pluripotency and self-renewal factors Oct4 and Nanog. In conclusion, gigantol possesses CSCs suppressing activity which may facilitate the development of this compound for therapeutic approaches by targeting CSCs.

No MeSH data available.


Related in: MedlinePlus

Gigantol reduces CSC markers. (a) After H460 cells were treated with gigantol (0–20 µM) for 48 h, cells were collected, and CSC markers, CD133 and ALDH1A1, were analyzed by Western blotting. The blots were reprobed with β-actin to confirm equal loading. (b) Band density was quantified by densitometry, and mean data from independent experiments were normalized to the controls. The bars are means ± SD (n = 3). ∗P < 0.05 versus nontreated cells.
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4539074&req=5

fig4: Gigantol reduces CSC markers. (a) After H460 cells were treated with gigantol (0–20 µM) for 48 h, cells were collected, and CSC markers, CD133 and ALDH1A1, were analyzed by Western blotting. The blots were reprobed with β-actin to confirm equal loading. (b) Band density was quantified by densitometry, and mean data from independent experiments were normalized to the controls. The bars are means ± SD (n = 3). ∗P < 0.05 versus nontreated cells.

Mentions: Having shown that gigantol suppressed the CSCs phenotypes in the lung cancer cells, we next confirmed such observation by determining the well-known lung CSC markers. The cells were cultivated in the presence or absence of gigantol for 48 h, and the expression levels of CD133 and ALDH1A1 were determined by Western blotting. Figure 4 shows that treatment of the cells with gigantol significantly suppressed CD133 and ALDH1A1 expressions in a dose-dependent manner, confirming that gigantol suppresses CSCs phenotypes in lung cancer cells.


Gigantol Suppresses Cancer Stem Cell-Like Phenotypes in Lung Cancer Cells.

Bhummaphan N, Chanvorachote P - Evid Based Complement Alternat Med (2015)

Gigantol reduces CSC markers. (a) After H460 cells were treated with gigantol (0–20 µM) for 48 h, cells were collected, and CSC markers, CD133 and ALDH1A1, were analyzed by Western blotting. The blots were reprobed with β-actin to confirm equal loading. (b) Band density was quantified by densitometry, and mean data from independent experiments were normalized to the controls. The bars are means ± SD (n = 3). ∗P < 0.05 versus nontreated cells.
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4539074&req=5

fig4: Gigantol reduces CSC markers. (a) After H460 cells were treated with gigantol (0–20 µM) for 48 h, cells were collected, and CSC markers, CD133 and ALDH1A1, were analyzed by Western blotting. The blots were reprobed with β-actin to confirm equal loading. (b) Band density was quantified by densitometry, and mean data from independent experiments were normalized to the controls. The bars are means ± SD (n = 3). ∗P < 0.05 versus nontreated cells.
Mentions: Having shown that gigantol suppressed the CSCs phenotypes in the lung cancer cells, we next confirmed such observation by determining the well-known lung CSC markers. The cells were cultivated in the presence or absence of gigantol for 48 h, and the expression levels of CD133 and ALDH1A1 were determined by Western blotting. Figure 4 shows that treatment of the cells with gigantol significantly suppressed CD133 and ALDH1A1 expressions in a dose-dependent manner, confirming that gigantol suppresses CSCs phenotypes in lung cancer cells.

Bottom Line: Importantly, gigantol significantly reduced the ability of the cancer cells to form tumor spheroids, a critical hallmark of CSCs.Concomitantly, the treatment of the compound was shown to reduce well-known lung CSCs markers, including CD133 and ALDH1A1.In conclusion, gigantol possesses CSCs suppressing activity which may facilitate the development of this compound for therapeutic approaches by targeting CSCs.

View Article: PubMed Central - PubMed

Affiliation: Cell-Based Drug and Health Product Development Research Unit, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok 10330, Thailand.

ABSTRACT
As cancer stem cells (CSCs) contribute to malignancy, metastasis, and relapse of cancers, potential of compound in inhibition of CSCs has garnered most attention in the cancer research as well as drug development fields recently. Herein, we have demonstrated for the first time that gigantol, a pure compound isolated from Dendrobium draconis, dramatically suppressed stem-like phenotypes of human lung cancer cells. Gigantol at nontoxic concentrations significantly reduced anchorage-independent growth and survival of the cancer cells. Importantly, gigantol significantly reduced the ability of the cancer cells to form tumor spheroids, a critical hallmark of CSCs. Concomitantly, the treatment of the compound was shown to reduce well-known lung CSCs markers, including CD133 and ALDH1A1. Moreover, we revealed that gigantol decreased stemness in the cancer cells by suppressing the activation of protein kinase B (Akt) signal which in turn decreased the cellular levels of pluripotency and self-renewal factors Oct4 and Nanog. In conclusion, gigantol possesses CSCs suppressing activity which may facilitate the development of this compound for therapeutic approaches by targeting CSCs.

No MeSH data available.


Related in: MedlinePlus